XL765, a pyridopyrimidinone-derivative, is a highly selective, potent and reversible ATP-competitive inhibitor of pan-Class I PI3K (α, β, γ, and δ) and mTORC1/mTORC2. It is orally active, highly selective over 130 other protein kinases. In cellular assays, XL765 inhibits the formation of PIP3 in the membrane, and inhibits phosphorylation of AKT, p70S6K, and S6 phosphorylation in multiple tumor cell lines with different genetic alterations affecting the PI3K pathway. In mouse xenograft models, oral administration of XL-765 results in dose-dependent inhibition of phosphorylation of AKT, p70S6K, and S6 with a duration of action of approximately 24 hours. Repeat dose administration of XL765 results in significant tumor growth inhibition in multiple human xenograft models in nude mice that is associated with antiproliferative, antiangiogenic, and proapoptotic effects.

KEYWORDS: XL-765 | Supplier | PI3K (α, β, γ, δ) and mTORC1/mTORC2 inhibitor |  Voxtalisib | SAR245409 | XL765 | XL 765 | SAR-245409 | SAR 245409 | CT-XL765 | CAS [934493-76-2] | Phosphatidylinositol | mTOR | PI3K | Inhibitor | Enzymes